However, one advantage of the inclusion of non-AF CABG patients as the control group is that they were treated with cardiovascular medications to a similar extent as AF patients (see Table 1), ruling out the potential involvement of pharmacological intervention on RyR2 cluster remodeling as a factor in observed results. This evidence concerns the gene RYR2 and atrial fibrillation.